IsoRay Continues to Support Innovative Techniques in Brain Cancer Treatment RICHLAND, Wash., May 30, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for...
We remain excited by the mounting evidence that certain types of recurrent cancerous brain tumors can be effectively treated with Cesium-131 brachytherapy, prolonging survival and improving quality of life at the same time. From Lisa Esposito and Kristine Crane in...
Key Presentation on Prostate Cancer: “Survivor Debate: Low-Intermediate Risk Prostate Cancer” will Feature Noted Brachytherapist, Dr. Ron Benoit, UPMC, as Panelist RICHLAND, Wash., May 16, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical...
Worse survival without [brachytherapy] boost in high-risk patients At long last, the mounting scientific evidence for the value of brachytherapy for prostate cancer treatment is starting to generate more awareness among the care community and associated industry...
RICHLAND, Wash., May 11, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological...
Year after year, the Isoray team attends the American Urological Association annual meeting - it is undoubtedly one of the events we look forward to most. During last year’s AUA meeting, there was limited data presented on the use of targeted (focal) therapy. In...
Fifth Consecutive Quarter of Year-Over-Year Revenue Increases RICHLAND, Wash., May 03, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American:ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment...
NEW YORK, NY, May 02, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological...
To the benefit of patients and urologists worldwide, focal therapy for prostate cancer bridges the sizable gap between active surveillance and radical prostatectomy. Its ability to provide effective disease control, minimize the potential for chronic incontinence and...
RICHLAND, Wash., April 26, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (the “Company”) (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and...
There is a growing amount of evidence that brachytherapy’s role as a prostate cancer treatment modality should not be limited to low-risk cases, but should also include patients with higher risk disease. The Journal of Clinical Oncology recently reported on an...
RICHLAND, Wash, April 18, 2018 (GLOBE NEWSWIRE) -- IsoRay, Inc. (NYSE American: ISR), a medical technology company and innovator in seed brachytherapy and medical radioisotope applications for the treatment of prostate, brain, lung, head and neck and gynecological...